Literature DB >> 20808246

Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD.

Emer Fitzpatrick1, Ragai R Mitry, Alberto Quaglia, Munther J Hussain, Ruth DeBruyne, Anil Dhawan.   

Abstract

BACKGROUND: With the alarming growth in prevalence of paediatric nonalcoholic fatty liver disease (NAFLD), there is a need for noninvasive methods of stratifying disease severity. Our aim was to evaluate a combination of serum biomarkers as a measure of disease activity in paediatric NAFLD. PATIENTS AND METHODS: Forty-five children with biopsy-proven NAFLD were enrolled. Caspase-cleaved CK18 fragments (CK18 M30), hyaluronic acid, leptin, and adiponectin were measured in serum using enzyme-linked immunosorbent assays and high-sensitivity C-reactive protein using a colorimetric assay.
RESULTS: Median age was 12.7 years (55% boys). Median body mass index z score was 1.7. CK18 M30 levels were significantly higher in patients with NAFLD versus controls, median 288 IU/L versus 172 IU/L (P < 0.001), and in those with steatohepatitis, median 347 IU/L versus simple steatosis (NAFLD activity score < 3), median 191 IU/L (P = 0.006). Significant fibrosis (≥F2) could be differentiated from no/minimal fibrosis (<F2), median 393 IU/L versus 243 IU/L (P = 0.03). Leptin could distinguish <F2 from ≥F2; 28.9 ng/mL versus 70.1 ng/mL (P = 0.037). Adiponectin, hyaluronic acid, and high-sensitivity C-reactive protein did not achieve significance in predicting steatohepatitis nor significant fibrosis.
CONCLUSIONS: The present study combines use of markers for different processes in the development of steatohepatitis. Serum biomarkers, especially CK18 M30, are useful in stratifying disease severity in paediatric NAFLD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20808246     DOI: 10.1097/MPG.0b013e3181e376be

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  40 in total

Review 1.  Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future.

Authors:  Emer Fitzpatrick; Anil Dhawan
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

2.  Methods to improve the noninvasive diagnosis and assessment of disease severity in children with suspected nonalcoholic fatty liver disease (NAFLD): Study design.

Authors:  Bryan Rudolph; Nicole Bjorklund; Nadia Ovchinsky; Debora Kogan-Liberman; Adriana Perez; Mark Liszewski; Terry L Levin; Michelle Ewart; Qiang Liu; Xiaonan Xue; Shankar Viswanathan; Howard D Strickler
Journal:  Contemp Clin Trials       Date:  2018-10-27       Impact factor: 2.226

3.  NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN).

Authors:  Miriam B Vos; Stephanie H Abrams; Sarah E Barlow; Sonia Caprio; Stephen R Daniels; Rohit Kohli; Marialena Mouzaki; Pushpa Sathya; Jeffrey B Schwimmer; Shikha S Sundaram; Stavra A Xanthakos
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-02       Impact factor: 2.839

Review 4.  Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach.

Authors:  Anna Alisi; Ariel E Feldstein; Alberto Villani; Massimiliano Raponi; Valerio Nobili
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-01-17       Impact factor: 46.802

5.  Keratin 18, Apoptosis, and Liver Disease in Children.

Authors:  Yanci O Mannery; Craig J McClain; Miriam B Vos
Journal:  Curr Pediatr Rev       Date:  2011-11

6.  Circulating levels of FGF-21 in obese youth: associations with liver fat content and markers of liver damage.

Authors:  Cosimo Giannini; Ariel E Feldstein; Nicola Santoro; Grace Kim; Romy Kursawe; Bridget Pierpont; Sonia Caprio
Journal:  J Clin Endocrinol Metab       Date:  2013-04-26       Impact factor: 5.958

Review 7.  Nonmedicinal interventions in nonalcoholic fatty liver disease.

Authors:  Manuela G Neuman; Radu M Nanau; Lawrence B Cohen
Journal:  Can J Gastroenterol Hepatol       Date:  2015 Jun-Jul

Review 8.  Controversy in the diagnosis of pediatric non-alcoholic fatty liver disease.

Authors:  Pierluigi Marzuillo; Anna Grandone; Laura Perrone; Emanuele Miraglia Del Giudice
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

9.  Circulating Soluble Fas and Fas Ligand Levels Are Elevated in Children with Nonalcoholic Steatohepatitis.

Authors:  Naim Alkhouri; Anna Alisi; Vera Okwu; Ammar Matloob; Federica Ferrari; Annalisa Crudele; Rita De Vito; Rocio Lopez; Ariel E Feldstein; Valerio Nobili
Journal:  Dig Dis Sci       Date:  2015-03-13       Impact factor: 3.199

Review 10.  Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease.

Authors:  Neven Baršić; Ivan Lerotić; Lea Smirčić-Duvnjak; Vedran Tomašić; Marko Duvnjak
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.